-
Quinazoline Program Makes Progress Toward Drug Treatment For Spinal Muscular Atrophy -- Families Of SMA 2010 Program Update
7/1/2010
Late last year, Families of Spinal Muscular Atrophy (FSMA) announced that it had entered into a groundbreaking exclusive license agreement with Repligen Corporation for the development of a potential treatment for Spinal Muscular Atrophy (SMA). FSMA is dedicated to creating a treatment and cure for SMA by funding and advancing comprehensive research and drug discovery programs
-
ACR Image Metrix Experts Present At The DIA Annual Meeting
6/30/2010
ACR Image Metrix, an imaging contract research organization (CRO) with expertise in imaging trial design, techniques and data extraction, gave live presentations at the 46th Annual Drug Information Association (DIA) Meeting, which was held June 13-17, 2010, in Washington, DC
-
Santarus Announces Launch Of Prescription ZEGERID Authorized Generic And Company Restructuring
6/30/2010
Santarus, Inc., a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of prescription ZEGERID (omeprazole/ sodium bicarbonate) Capsules in 20 mg and 40 mg dosage strengths in the U.S. under the Prasco label.
-
Cerep Chooses Cameleon Software To Develop International Growth
6/30/2010
Cameleon Software, the global leader in product design, sales configuration, quotes, and proposals software, recently announced that Cerep, a strategic partner in the medical drug discovery sector, has chosen to outfit its sales teams in France, the United States and China with Cameleon's software
-
Dacogen (Decitabine) For Injection Phase III AML Results Announced
6/30/2010
SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care. Overall survival was the primary endpoint of this study. While Dacogen did not achieve statistically significant
-
BioSante Pharmaceuticals Announces Positive Clinical Results In Pill-Plus Oral Contraceptive Study
6/30/2010
BioSante Pharmaceuticals, Inc. announced recently positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05). The study was a Phase II double-blind randomized clinical trial in 82 women comprising a cross-over design of two treatment periods of five months each
-
AVEO Pharmaceuticals’ Human Response Platform And Proprietary Mouse Models Featured In Nature Reviews Cancer
6/30/2010
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the publication of a cover article in the current issue of Nature Reviews Cancer summarizing the recent development of improved preclinical modeling approaches to cancer drug development. Citing the accelerated discovery of new cancer genes emerging from large-scale cancer genomics as well as the extensive number of new compounds emerging from the drug discovery pipeline, the
-
OSHA, EPA, ISO, GMP Quality And Safety Requirements Eased With Quality Management Software
6/30/2010
Chemicals manufacturers must comply with GMP, OSHA, EPA, ISO, and other quality and safety requirements. The ability to log, manage and report on quality management-related information is a key requirement in meeting industry best practices and regulatory requirements.
-
Emerald BioStructures And FORMA Therapeutics Enter Strategic Cancer Research Partnership
6/29/2010
Emerald BioStructures, a leading provider of integrated structural biology services, and FORMA Therapeutics, a drug discovery company, today announced the signing of a strategic partnership for the structure-based design of cancer drug candidates for FORMA's pipeline.
-
HHS Secretary Sebelius To Join Leaders From NIH, FDA ,And Academia To Discuss New Roles In Drug Discovery And Development
6/29/2010
U.S. Secretary of Health and Human Services Kathleen Sebelius and other national leaders are coming together on July 6, 2010 for a first-of-its-kind town hall-style meeting with the goal of accelerating the discovery and development of new cancer drugs.
